Anesthesiology and Pain Medicine

Published by: Kowsar

The Effect of Adding Sufentanil to 0.5% Hyperbaric Bupivacaine on Duration of Brachial Plexus Blockade in Chronic Opium Abusers: a Randomized Clinical Trial

Omid Azimaraghi 1 , Seyed Mojtaba Marashi 1 , Noushin Khazaei 2 , Sarah Pourhassan 3 and Ali Movafegh 1 , *
Authors Information
1 Department of Anesthesiology, Pain and Critical Care, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Anesthesiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Article information
  • Anesthesiology and Pain Medicine: June 01, 2015, 5 (3); e21960
  • Published Online: June 22, 2015
  • Article Type: Research Article
  • Received: July 12, 2014
  • Revised: October 4, 2014
  • Accepted: November 11, 2014
  • DOI: 10.5812/aapm.21960v2

To Cite: Azimaraghi O, Marashi S M, Khazaei N, Pourhassan S, Movafegh A. The Effect of Adding Sufentanil to 0.5% Hyperbaric Bupivacaine on Duration of Brachial Plexus Blockade in Chronic Opium Abusers: a Randomized Clinical Trial, Anesth Pain Med. 2015 ; 5(3):e21960. doi: 10.5812/aapm.21960v2.

Abstract
Copyright © 2015, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. World drug report 2012. 2012;
  • 2. Mokri A. Brief overview of the status of drug abuse in Iran. Arch Iranian Med. 2002; 5(3): 184-90
  • 3. Moharreri MR. General view of drug abuse in Iran and one-year report of outpatient treatment of opiate addiction in the city of Shiraz. NIDA Res Monogr. 1978; (19): 69-81[PubMed]
  • 4. Day C, Nassirimanesh B, Shakeshaft A, Dolan K. Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduct J. 2006; 3: 2[DOI][PubMed]
  • 5. Dabbagh A, Dahi-Taleghani M, Elyasi H, Vosoughian M, Malek B, Rajaei S, et al. Duration of spinal anesthesia with bupivacaine in chronic opium abusers undergoing lower extremity orthopedic surgery. Arch Iran Med. 2007; 10(3): 316-20[PubMed]
  • 6. Rapp SE, Ready LB, Nessly ML. Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain. 1995; 61(2): 195-201[PubMed]
  • 7. Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology. 2004; 101(1): 212-27[PubMed]
  • 8. Vosoughian M, Dabbagh A, Rajaei S, Maftuh H. The duration of spinal anesthesia with 5% lidocaine in chronic opium abusers compared with nonabusers. Anesth Analg. 2007; 105(2): 531-3[PubMed]
  • 9. Gupta S, Dev K, Katyal S, Kathuria S. Intrathecal fentanyl with 0.5% bupivacaine heavy in chronic opium abusers. South Afr J Anaesth Analg. 2012; 18(2)
  • 10. Safari F, Dabbagh A, Sharifnia M. The effect of adjuvant midazolam compared with fentanyl on the duration of spinal anesthesia with 0.5% bupivacaine in opium abusers. Korean J Anesthesiol. 2012; 63(6): 521-6[PubMed]
  • 11. Dahi-Taleghani M, Fazli B, Ghasemi M, Vosoughian M, Dabbagh A. Effect of intravenous patient controlled ketamine analgesiaon postoperative pain in opium abusers. Anesth Pain Med. 2014; 4(1)[PubMed]
  • 12. Zirak N, Soltani G, Javdani N, Shamloo AS, Bameshki A, Peyvandi A. Effect of Fentanyl in Spinal Anesthesia With Bupivacaine in Opium Abusers. Razavi Int J Med. 2014; 2(1)
  • 13. Hassani V, Movassaghi G, Safaian R, Safari S, Zamani MM, Hajiashrafi M, et al. Bupivacaine-sufentanil versus bupivacaine-fentanyl in spinal anesthesia of patients undergoing lower extremity surgery. Anesth Pain Med. 2014; 4(2)[DOI][PubMed]
  • 14. Bernstein MA, Welch SP. mu-Opioid receptor down-regulation and cAMP-dependent protein kinase phosphorylation in a mouse model of chronic morphine tolerance. Brain Res Mol Brain Res. 1998; 55(2): 237-42[PubMed]
  • 15. Rogers NF, el-Fakahany E. Morphine-induced opioid receptor down-regulation detected in intact adult rat brain cells. Eur J Pharmacol. 1986; 124(3): 221-30[PubMed]
  • 16. Mann A, Illing S, Miess E, Schulz S. Different mechanisms of homologous and heterologous mu-opioid receptor phosphorylation. Br J Pharmacol. 2014; [DOI][PubMed]
  • 17. Shannon HE, Lutz EA. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats. Neuropharmacology. 2002; 42(2): 253-61[PubMed]
  • 18. Stein C, Schafer M, Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med. 2003; 9(8): 1003-8[DOI][PubMed]
  • 19. Labuz D, Mousa SA, Schafer M, Stein C, Machelska H. Relative contribution of peripheral versus central opioid receptors to antinociception. Brain Res. 2007; 1160: 30-8[DOI][PubMed]
  • 20. Stein C. Targeting pain and inflammation by peripherally acting opioids. Front Pharmacol. 2013; 4: 123[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments